MAPT and Alzheimer disease: Our third objective was to evaluate the unique influence of the SD/FHS-CVD risk score combined risk on an incident aMCI diagnosis at a UDS follow-up beyond that of commonly used AD biomarkers, including levels of CSF-Aβ, CSF-Tau, and CSF-PTau and hippocampal volume.